340 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Allergan Plc (AGN) CEO Brent Saunders on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4236451-allergan-plc-agn-ceo-brent-saunders-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Jan 29, 2019 - Allergan Plc (NYSE:AGN) Q4 2018 Earnings Conference Call January 29, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Investor Relations Brenton L. Saunders - Chairman, President & CEO W
Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid http://www.zacks.com/stock/news/350482/allergan-agn-q4-earnings-beat-estimates-2019-view-tepid?cid=CS-ZC-FT-350482 Jan 29, 2019 - Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN http://www.zacks.com/stock/news/350052/drug-biotech-stock-earnings-on-jan-29-pfe-amgn-biib-agn?cid=CS-ZC-FT-350052 Jan 28, 2019 - Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III http://www.zacks.com/stock/news/349758/amgen-allergans-rituxan-biosimilar-meets-goal-in-phase-iii?cid=CS-ZC-FT-349758 Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders http://www.zacks.com/stock/news/349476/ironwood-commences-phase-i-study-on-iw-6463-for-cns-disorders?cid=CS-ZC-FT-349476 Jan 24, 2019 - Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes? https://www.fool.com/investing/2019/01/20/which-big-pharma-stocks-lose-most-in-a-war-on-drug.aspx?source=iedfolrf0000001 Jan 20, 2019 - The answer: It's complicated.
Drugmakers Raise Prices Amid Shortages, Recalls https://www.wsj.com/articles/drugmakers-raise-prices-amid-shortages-recalls-11547807400?mod=pls_whats_news_us_business_f Jan 18, 2019 - The increases can mean higher costs for pharmacies and patients on what are generally cheaper generic drugs. Drugmakers say the price increases reflect higher costs they have incurred to help fill supply voids.
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C http://www.zacks.com/stock/news/347742/ironwoods-irwd-linzess-gets-approval-in-china-for-ibs-c?cid=CS-ZC-FT-347742 Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-ZC-FT-347005 Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

Pages: 12345678910...34

<<<Page 5>